81469a6772
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md - Domain: health - Claims: 2, Entities: 1 - Enrichments: 2 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
49 lines
No EOL
2.4 KiB
Markdown
49 lines
No EOL
2.4 KiB
Markdown
# LIXIPARK Trial
|
|
|
|
**Type:** Phase 2 randomized controlled trial
|
|
**Drug:** Lixisenatide (GLP-1 receptor agonist)
|
|
**Indication:** Early Parkinson's disease
|
|
**Status:** Completed, published NEJM April 2024
|
|
**Primary Endpoint:** MDS-UPDRS Part III motor score at 12 months — MET (statistically significant)
|
|
|
|
## Design
|
|
- **N:** 156 patients (75 lixisenatide, 75 placebo; some sources report 150)
|
|
- **Duration:** 12 months
|
|
- **Population:** Early Parkinson's disease (<3 years since diagnosis)
|
|
- **Blinding:** Double-blind
|
|
- **Delivery:** Daily subcutaneous injection
|
|
|
|
## Results
|
|
**Primary Endpoint (12 months):**
|
|
- Placebo: MDS-UPDRS Part III worsened +3.04 points (disease progression)
|
|
- Lixisenatide: Remained at baseline (0 change)
|
|
- Between-group difference: Statistically significant
|
|
- **Interpretation:** Lixisenatide halted motor symptom progression over 12 months
|
|
|
|
**Safety:**
|
|
- >50% of lixisenatide patients: significant GI side effects (nausea, vomiting)
|
|
- >1/3 required dose reduction due to GI tolerability
|
|
- Safety profile is major practical concern for real-world use
|
|
|
|
## Limitations
|
|
- Phase 2 (not Phase 3 — not definitive)
|
|
- 12 months (shorter than exenatide Phase 3 at 96 weeks)
|
|
- No DaT-SPECT brain imaging to confirm neuroprotection vs symptomatic benefit
|
|
- Off-label use NOT recommended pending Phase 3 confirmation
|
|
|
|
## Mechanistic Context
|
|
Holscher 2024 review identifies lixisenatide as having "strongest neuroprotective effect" among GLP-1 agonists in clinical trials, correlating with BBB penetrance via adsorption transcytosis. This may explain divergence from exenatide Phase 3 failure, where CSF analysis showed insufficient drug reaching substantia nigra.
|
|
|
|
## Publication
|
|
- **Journal:** New England Journal of Medicine
|
|
- **Date:** April 4, 2024
|
|
- **DOI:** 10.1056/NEJMoa2312323
|
|
- **Preliminary results:** Presented at 2023 International Parkinson and Movement Disorder Society congress, Copenhagen
|
|
|
|
## Follow-up Status
|
|
No Phase 3 funding announced as of May 2026. Exenatide Phase 3 failure (Lancet February 2025) may have chilled further GLP-1 Parkinson's trial investment.
|
|
|
|
## Timeline
|
|
- **2023-09** — Preliminary results presented at International Parkinson and Movement Disorder Society congress, Copenhagen
|
|
- **2024-04-04** — Full results published in NEJM, primary endpoint met with statistical significance
|
|
- **2024-2026** — No Phase 3 funding materialized despite positive Phase 2 results |